PD269 - SAFETY AND PHARMACEUTICAL STABILITY OF PARENTERAL MICRONUTRIENT SUPPLEMENTATION IN MAJOR BURN PATIENTS: AN ESPEN-ORIENTED APPROACH

PD269

SAFETY AND PHARMACEUTICAL STABILITY OF PARENTERAL MICRONUTRIENT SUPPLEMENTATION IN MAJOR BURN PATIENTS: AN ESPEN-ORIENTED APPROACH

C. Pellicer Franco^1,*, C. Manso Murcia²

¹Hospital Pharmacy, ²Intensive Care, Hospital VIrgen de la Arrixaca, Murcia, Spain

 

Rationale: According to the ESPEN micronutrient guideline (2024) parenteral supplementation may be necessary in cases of impaired absorption or increased requirements. Major burn patients are at high risk of micronutrient depletion.This study evaluates the safety, feasibility, and pharmaceutical stability of a compounded intravenous micronutrient formulation desing to treat  major burn patients

Methods: Prospective observational study (2 years) in an adult ICU. Patients with >20% total body surface area burns

A parenteral solution was designed according to ESPEN guidelines. Consultations were held with pharmaceutical laboratories to ensure its physicochemical stability.This solution was administered daily for the specified time according to the body surface area burned.

Monitoring: Baseline and weekly plasma micronutrient levels. They were also collected adverse events and biochemical safety

Descriptive analysis of patient demographics and the evolution of micronutrients  levels

Results: Four patients were included in the study, mean age 46.8 years (20-65), with a burned body surface of 41.2% (20-60), who received treatment for a mean of 14.3 days (10-17)

Plasma levels reached the optimal values in most patients. No  complications associated with the infusion, no significant adverse events and no visible precipitation or incompatibilities were observed

Image:

 

Conclusion: Parenteral supplementation of micronutrients in major burn patients appears to be a safe, feasible, and pharmaceutically stable strategy.These findings are aligned with ESPEN guidance and support the integration of standardized parenteral micronutrient protocols into routine clinical practice

However, the observational design and limited sample size restrict the generalizability of the results. Further research is warranted to evaluate the impact of this strategy on clinical outcomes  in this high-risk population.

Disclosure of Interest: None declared